Program Announcement for the Defense Health Agency

Prostate Cancer Research Program Physician Research Award

Funding Opportunity Number: HT942526PCRPPRA

Pre-Application Due: August 12, 2026

Application Due: September 2, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click** ⓘ **to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Physician Research Award (PRA) supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. All applications must address one of the FY26 PCRP Overarching Challenges.

Distinctive Features:

- **Early-Career Clinician Investigator:** Serves as the Principal Investigator (PI). Includes investigators with clinical duties in the last year of an accredited medical residency or medical fellowship program, or within five years of initiating a faculty appointment.
- **Mentorship:** Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship.
- **Researcher Development Plan:** Applications must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the projects and foster the PI's career development.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $8.8M to fund approximately 8 Physician Research Award applications with total cost caps of $1.1M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern Time (ET), August 12, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, September 2, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, September 8, 2026
- **Peer Review:** November 2026
- **Programmatic Review:** March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526PCRPPRA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Early-career physician investigators with clinical duties and/or responsibilities affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application, regardless of ethnicity, nationality or citizenship status. To qualify as an early-career physician investigator, by the application submission deadline, the investigator must be ONE of the following criteria:

- In the last year of an accredited graduate medical education programs, either as a resident or fellow.
- Within five years of initiating their first faculty appointment, including instructor positions or equivalent.

An investigator may be named as a PI on a single application to this program announcement. If an investigator is named multiple times as a PI, only the first application received will be accepted; additional applications will be administratively withdrawn.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Prostate Cancer Research Program (PCRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the PCRP in 1997 to promote innovative research focused on eradicating prostate cancer. Appropriations for the PCRP from FY97 through FY25 totaled $2.445 billion. The FY26 appropriation is $75 million (M).

The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research.

3.1. Intent of the Physician Research Award

The FY26 PCRP Physician Research Award (PRA) supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The application should name the early-career physician as the PI of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational or clinical prostate cancer research. ***As the PI, the early-career physician should write all application components for the FY26 PCRP Physician Research Award with appropriate direction from the mentor(s).***

3.1.1. Overarching Challenges for the PRA

All applications must address one of the following FY26 PCRP overarching challenges:

- **Improve overall health, wellness and survivorship for those impacted by prostate cancer**

  Applications should aim to accelerate knowledge that translates to improve overall health and survivorship for those impacted by prostate cancer, with the goal of enhancing quality of life, overall health and survival, emotional health, healthy aging, cause-specific survival, cognitive function and other aspects of survivorship. Areas of particular interest include:

  - Biological basis of prostate cancer and its treatments on quality of life
  - The mental and emotional health of patients and their families/caregivers
  - Identification of groups of patients and their families at high risk of detriments in health and well-being
  - Implementation of factors or interventions that improve access to evidence-based care, quality-of-life outcomes and overall health and wellness

- **Develop new treatments or improve upon existing therapies to improve outcomes for patients with lethal prostate cancer**

  Applications must be directly related to prostate cancer with a high risk of death, including high-risk localized disease, regional disease and/or metastatic prostate cancer.

Treatments may address any stage in the continuum of care, including local therapies such as surgery or radiation designed to treat patients with a high risk of death from the disease. Proposed treatments are highly encouraged to consider preserving patient quality of life and not focus only on survival outcomes.

Applications should not focus on active surveillance or low-risk to intermediate-risk prostate cancer. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).

- **Enhance clinical care for all patients with prostate cancer**

  **Special emphasis on high-risk groups*

  Applications must be directly relevant to better understanding and/or reduction of factors that impact a person, their family or their caregiver's ability to prevent, detect, manage and survive prostate cancer.

  Factors may include physical, mental or emotional health differences experienced primarily in populations at high risk for prostate cancer, including Service Members and Veterans.

- **Define the biology of prostate cancer progression to lethal prostate cancer to reduce death**

  Applications must be directly related to high-risk, very high-risk and metastatic prostate cancer. The FY26 PCRP also strongly encourages research involving patient-derived materials or specimens related to ongoing or completed clinical trials.

  Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).

3.1.2. Key Elements for the PRA

- **Principal Investigator:** Physicians with clinical duties and/or responsibilities who, at the application submission deadline, are either in the last year of an accredited graduate medical education program as a resident or fellow or within five years of having initiated the first faculty appointment (including Instructor positions) are eligible to serve as the PI. Clinical duties include direct patient care, clinical teaching or clinical consultation, comprising at least 20% of professional effort at the time of application submission. The PI must demonstrate a commitment to a career as a physician-scientist and investigator at the forefront of prostate cancer research and clinical practice; however, the PI need not have previous prostate cancer research experience. The award should provide protected time for the PI to conduct prostate cancer research. The PCRP expects applications to demonstrate protection of at least 20% of the PI's time for prostate cancer research overall (this may include effort on this award plus other prostate cancer research projects). At minimum, the PI must dedicate sufficient effort to this specific award to complete the proposed research within the project timeline; this effort must be clearly stated in the budget justification.
- **Mentor(s):** This award requires the involvement of at least one designated mentor with an established research program in prostate cancer, as evidenced by recent publications, active funding and successful mentorship. In addition, the mentor(s) must demonstrate a commitment to advancing the PI's career in prostate cancer research. Mentors will be considered "key" for purposes of prior approval. Requests for changes in mentors will require a statement addressing changes to the Researcher Development Plan, if applicable.

- **Research Approach:** Proposed research ideas must address one or more of the FY26 PCRP Overarching Challenges. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The application should clearly articulate the feasibility of the research design and methods and a clear plan for achieving the proposed project goals. The PCRP encourages, but does not require, including ***preliminary data relevant to prostate cancer and the proposed project.*** Any preliminary data provided should originate from the PI, mentor(s) or member(s) of the collaborating team. Additionally, applications should identify and provide supporting documentation for required resources. The award can support ***research involving human subjects but not clinical trials.*** The PCRP encourages applications proposing correlative studies associated with an existing clinical trial, provided they are of no greater than minimal risk per the Institutional Review Board (IRB) of record and the Defense Health Agency Research & Development-Medical Research and Development Command (DHA R&D-MRDC) Office of Research and Regulatory Compliance (ORRC), Office of Human Research Oversight.
- **Researcher Development Plan:** Applications must include an ***individualized*** researcher development plan prepared with appropriate guidance from the mentor(s). The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PI's development as an independent prostate cancer physician-scientist. The application should describe an environment appropriate to the proposed mentoring and research project or describe how collaboration(s) with other institutions mitigate any deficiencies of resources and/or mentorship at the PI's institution. If the PI will utilize resources at another institution to successfully complete the proposed project, then the PCRP strongly encourages designating a co-mentor at the collaborating institution.
- **Impact:** Applications must address and provide a solution to one or more of the FY26 PCRP Overarching Challenges. The application should clearly describe the potential impact of the research, both short-term and long-term, in addressing the FY26 PCRP overarching challenge(s). High-impact research will, if successful, significantly advance prostate cancer research and/or patient care.

3.1.3. Other Important Considerations for the PRA

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Clinical trials are not allowed within this funding opportunity.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the ARRIVE 2.0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research

relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

The following encouragement is broadly applicable across many CDMRP programs, including the PCRP, A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY26 PCRP priorities.

3.2. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.3. Funding Details

Period of Performance: The maximum period of performance is **4** years.

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **$1.1M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **4** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for one investigator to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 PCRP Physician Research Award.
- Clinical research costs.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Clinical trial costs.
- Equipment.
- Salary support for the mentor(s) or any other senior/key personnel except the PI.

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

Pre-application submissions must include the following components.

LOI (one-page limit): Provide a brief description of the research to be conducted. Include the FY26 PCRP Overarching Challenge the research will address.

4.3. Full Application Components

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative (10-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed project in detail using the outline below. ***The PI should write the project narrative while showing appropriate direction from the mentor(s).***

  - **Principal Investigator:** The application should describe the PI's career goals, demonstrating a strong personal commitment to pursuing an independent career as a leader at the forefront of prostate cancer research and patient care. Describe how the proposed research project and mentoring experience will promote the PI's development toward becoming an independent prostate cancer physician-scientist. The application should discuss the PI's career plans and research plans after the completion of this award.
  - **Mentor(s):** Describe each mentor or co-mentor's background and experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications and successful mentorship. Explain how the mentor(s) will assist the PI throughout the period of performance in developing toward

independence in prostate cancer research. Provide details on the amount and types of interactions between the mentor(s) and the PI. Describe the track record of each mentor for mentoring early career investigators in prostate cancer research.

- **Research Project:** Describe the proposed research project, including the background, hypothesis/objective, specific aims, experimental design, methods and analyses, including the appropriate controls. The application must provide a sound scientific rationale for the proposed project and its feasibility as established through a critical review and analysis of published literature and/or logical reasoning. ***Applications allow, but do not require, preliminary data to support the scientific rationale and feasibility of the research approaches.*** Include a statistical analysis plan for the proposed research and a power analysis to support the design and sample size (if applicable). Address potential problem areas and present alternative methods and approaches. Describe how to determine the clinical relevance of the anticipated findings, if applicable. Explain how the study design incorporates cell line authentication and/or statistical rigor of preclinical experiments, if applicable. Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. For clinical research, see Attachment 9 for the required strategy for the inclusion of women and minorities appropriate to the objectives of the study.
- **Overarching Challenges:** Briefly describe how the proposed research will help address and provide a solution to one or more of the FY26 PCRP Overarching Challenges.

If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the GAI, Appendix 4, for additional considerations.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
- **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support:**
  - ***Letter(s) from the Mentor(s):*** Provide letter(s) of recommendation(s) from the mentor(s).
  - ***Letters(s) of Collaboration:*** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work.
  - ***Letter(s) Signifying Access:*** If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.
- **Research Sharing Plan:** Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

  Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan, which will be requested only after a recommendation for funding is made.

  Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

  Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.
  - **Background:** Present the scientific rationale behind the proposed research project.
  - **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached.

- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design, including appropriate controls.
- **Military Relevance:** Describe how the study is relevant to military health.
- **Personnel:** Describe the following:
  - The PI's career goals and potential for a career at the forefront of prostate cancer research.
  - The strategy for acquiring necessary skills, competence and expertise to successfully complete the proposed research project.
  - The mentor's (and co-mentor's, if applicable) background and experience in prostate cancer research and proposed contribution to the career development of the PI.
  - How the proposed research project will prepare the PI for a career at the forefront of prostate cancer research.
- **Impact:** Summarize how the proposed research will address and provide a solution to one or more of the FY26 PCRP Overarching Challenges and ultimately provide progress toward eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers experiencing the impact of the disease.

- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

- Summarize the objectives and rationale for the proposed research.
- What are the likely contributions of this study to the FY26 PCRP Overarching Challenges?
- What population will the research help, and how will it help them?
- What are the potential applications, benefits and risks of the anticipated outcomes?
- What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?
- What is the potential benefit of the proposed study and the anticipated outcomes to Service Members, Veterans and/or their Families?
- Describe the PI's career goals in prostate cancer research and patient care.
  - How does the research plan support the PI in achieving these goals?
  - How do the mentorship and researcher development plan support the PI in achieving these goals?

- **Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic

Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

- **Attachment 6: Researcher Development Plan (two-page limit): Upload as "ResearchDev.pdf".**
  - Clearly articulate an ***individualized strategy*** that will enable the PI to acquire the necessary skills, competence and expertise to successfully complete the proposed research project.
  - Indicate how the ***individualized*** researcher development plan will provide the PI with an opportunity to develop a research project, investigate a problem or question in the field of prostate cancer, and effectively prepare the PI for a career as an independent prostate cancer physician-scientist.
  - Describe how the environment and mentorship supports the researcher development plan, including a description of ongoing prostate cancer research at the institution. Include a description of the environment of any collaborating institutions that will augment the lack of specific resources at the PI's primary institution (if applicable). If the PI will utilize resources at another institution to successfully complete the proposed project, then the PCRP strongly encourages designating a co-mentor at the collaborating institution. Include information on collaborations with other investigators, seminars, workshops, and other opportunities for professional interaction with leaders in the prostate cancer field. ***The application cannot involve members of the FY26 PCRP Programmatic Panel.***
- **Attachment 7: Impact Statement (one-page limit): Upload as "Impact.pdf".** Explain in detail why the proposed research project is important as follows:
  - **Describe the short-term impact:** Detail the anticipated outcome(s)/product(s) directly attributed to the results of the proposed research, including any clinically relevant results. Summarize how the anticipated outcome(s)/product(s) address(es) and will help provide a solution to one or more of the FY26 PCRP Overarching Challenges.
  - **Describe the long-term impact:** Explain the anticipated long-term gains from the proposed research, including the anticipated advantages that the new understanding may contribute to the goal of elimination of death and suffering from prostate cancer.
  - **Describe the relevance to military health:** Briefly describe how the proposed research is relevant to Service Members, Veterans and/or their Families.
- **Attachment 8: Eligibility Statement (one-page limit): Upload as "Eligibility.pdf".** Provide a letter, signed by the PI and the Department Chair, Dean, or equivalent official, verifying that the eligibility requirements have been met by the application submission deadline. If the PI is in the last year of an accredited graduate medical education program, either as a resident or fellow, provide the date (month/year) the PI will complete their medical residency or fellowship. For PIs with a faculty appointment, provide the date (month/year) the PI began the appointment to verify that he/she is within five years of having initiated their first faculty appointment (including instructor positions).
- **Attachment 9: Inclusion of Women and Minorities (four-page limit): Upload as "Inclusion.pdf".** ***(Attachment 9 is only applicable and required for applications that propose clinical research.)*** Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the

composition of the proposed study population in terms of sex, racial and ethnic group, and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from IRB review) are exempt from this requirement. The "Public Health Service (PHS) Inclusion Enrollment Report" is a three-page fillable PDF form, that can be downloaded from eBRAP.

- **Attachment 10: Transition Plan (one-page limit): Upload as "Transition.pdf".** Provide information on potential methods and strategies to move the project's findings to the next phase of development, clinical trials, and/or delivery to the commercial market after successful completion of the award (e.g., specific potential industry partners, specific funding opportunities to apply for). Provide a realistic timeline for near-term clinical investigation. In addition, provide a plan to distribute the findings or intervention to the prostate cancer community.
- **Attachment 11: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.
- **Attachment 12: Suggested Intragovernmental/Intramural Budget Form *(if applicable)*: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

	Grants.gov	eBRAP.org
i. Research & Related Senior/Key Person Profile (Expanded)		
○ **Biographical Sketch**		
○ **Current/Pending Support** *Intragovernmental applicants must include their internally supported research and development programs.*		
ii. Research & Related Budget		
iii. Project/Performance Site Location(s)		
iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*		

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526PCRPPRA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization and contracting organization must be consistent throughout the entire

pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the application verification period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.

Members of the FY26 PCRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 PCRP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

Pre-applications submitted to this funding opportunity are used for program planning purposes only (e.g., reviewer recruitment) and will not be screened.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Principal Investigator**
  - How well the PI's achievements (as reflected by academic performance, awards, honors and/or previous publications and funding) indicate the potential for a successful career as a prostate cancer physician-scientist.
  - To what extent the PI's achievements and stated career goals demonstrate potential for a successful career in prostate cancer research and patient care.
  - To what extent the letters of recommendation from the mentor(s) and others support the PI's potential for highly productive career as an independent prostate cancer researcher in addition to continuing practice as a physician.

- Whether the proposed PI level of effort is appropriate for completion of the proposed work.

- **Mentor(s)**
  - Whether there is at least one mentor who is an established prostate cancer researcher, as evidenced by a demonstrated record of active funding and recent publications in prostate cancer research.
  - How well the mentor's (and co-mentor's, if applicable) own experience in prostate cancer research and their ongoing research program and available resources support the ability to supervise the PI's research project.
  - To what extent the track record(s) of the mentor(s) in previously mentoring early career investigators indicate the potential for successful mentoring of the PI in prostate cancer research.
  - Whether the mentor letter(s) indicate a high level of commitment to the PI's development as an independent prostate cancer researcher.
  - Whether the quality of the application suggests that the mentor(s) provided appropriate guidance in its preparation.
- **Research Strategy and Feasibility**
  - How well the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of the literature, prostate cancer-relevant preliminary data (if included) and/or logical reasoning.
  - Whether the experimental design and the statistical analysis plan, if applicable, are appropriate for the research proposed.
  - How well the hypotheses or objectives, aims, experimental design, methods and analyses are developed.
  - How well the application acknowledges potential problems and addresses alternative approaches.
  - As applicable, how well the application incorporates best practices for research rigor and reproducibility of experiments, including cell line authentication (if cell-based studies are proposed), statistical rigor of preclinical experiments (if animal or in vitro studies are proposed) and/or experiments to address clinical relevance (if translational research is proposed).
  - If applicable, to what degree the intellectual and material property plan is appropriate.
  - If the proposed research involves human subjects (excluding studies using de-identified biospecimens or datasets), whether the strategy for inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research objectives.
  - To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.

- **Researcher Development Plan and Environment**
  - How well the application outlines an individualized researcher development plan that will enable the PI to acquire the necessary skills, competence, and expertise to successfully complete the proposed research project.
  - How well the individualized researcher development plan is designed to prepare the PI for independence in prostate cancer research.
  - To what extent the scientific environment at the primary institution (and collaborating institution(s), if applicable) is appropriate for the proposed research and career development activities, including availability of professional interaction with established prostate cancer researchers.
  - To what degree the organizational commitment to adjust the PI's clinical or other responsibilities to secure additional time for research will help foster the PI's research and clinical career.
  - To what extent the research requirements are adequately supported by the availability and accessibility of facilities and resources (including collaborative arrangements and/or intellectual property plans as applicable).
- **Impact**
  - To what extent the anticipated outcomes of the proposed study will make an impact in the field and/or improve patient care/outcomes.
  - To what degree the anticipated short-term outcome(s)/product(s) of the project will address and provide a solution to one or more of the FY26 PCRP Overarching Challenges.
  - To what degree the proposed research would, in the long term, make an impact on prostate cancer patient care and ultimately contribute to the goal of eliminating death from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans and all the patients and caregivers who experience the impact of the disease.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria.** Unscored criteria are not assigned numerical scores but are evaluated qualitatively and may be discussed during panel review. Significant strengths or weaknesses in unscored criteria may influence the overall score and funding recommendation. For example, an inadequate budget or poorly written application may reduce confidence in the application despite strong scored criteria.

- **Personnel**
  - How appropriate the expertise and levels of effort are for other key personnel (excluding the PI and mentor, who are evaluated under scored criteria) for successful conduct of the proposed work.
- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 PCRP, as evidenced by the following:
  - Adherence to the intent of the funding opportunity
  - Programmatic relevance to the FY26 PCRP Overarching Challenges
  - Relative impact

6.3. Application Review and Selection Process

6.3.1. Pre-Application

There is no review and selection process for pre-applications submitted to this funding opportunity. ***CDMRP will NOT provide an invitation to submit a full application after pre-application submission.*** Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other

information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the PCRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D ORRC, prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), IRB or Ethics Committee (EC) review.

8.2. Reporting

Annual technical progress reports, as well as a final technical progress report, will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

PHS Inclusion Enrollment Reporting ***(required for applications proposing clinical research):*** Enrollment reporting on the basis of sex, race and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on eBRAP.

Award Expiration Transition Plan: An Award Expiration Transition Plan, using the template available on eBRAP, must be submitted with the final progress report.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

Changes in PI and/or mentor are not allowed, except under extenuating circumstances that will be evaluated on a case-by-case basis.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- Pre-application was not submitted.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 PCRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.

- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- More than one application is received naming the same investigator as PI. Only the first application received will be accepted; additional applications will be administratively withdrawn.
- The PI does not meet the eligibility criteria.
- The application does not address at least one of the FY26 PCRP Overarching Challenges.
- The application proposes a clinical trial.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded
SF424 Research & Related Application for Federal Assistance ***(Grants.gov submissions only)***	☐
Summary (Tab 1) and Application Contacts (Tab 2) ***(eBRAP submissions only)***	☐
Attachments	
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐
Researcher Development Plan – Attachment 6, upload as "ResearchDev.pdf"	☐
Impact Statement – Attachment 7, upload as "Impact.pdf"	☐
Eligibility Statement – Attachment 8, upload as "Eligibility.pdf"	☐
Inclusion of Women and Minorities – *(if applicable)* Attachment 9, upload as "Inclusion.pdf"	☐
Transition Plan – Attachment 10, upload as "Transition.pdf"	☐
Representations *(Grants.gov submissions only)* – Attachment 11, upload as "RequiredReps.pdf"	☐
Suggested Intragovernmental/Intramural Budget Form *(if applicable)* – Attachment 12, upload as "IGBudget.pdf"	☐
Additional Application Materials	
Research & Related Senior/Key Person Profile (Expanded)	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐
Research & Related Budget	☐
Project/Performance Site Location(s)	☐
Research & Related Subaward Budget Attachment(s) *(if applicable)*	☐

Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting In Vivo Experiments
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHA R&D-MRDC	Defense Health Agency Research and Development Medical Research and Development Command
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
GAI	General Application Instructions
IACUC	Institutional Animal Care and Use Committee
IRB	Institutional Review Board
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
ORRC	Office of Research and Regulatory Compliance
PCRP	Prostate Cancer Research Program
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
PRA	Physician Research Award
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs